The stock price of AbCellera Biologics Inc (NASDAQ: ABCL) has surged by 5306582 when compared to previous closing price of 3.41, but the company has seen a 4.06% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-03 that ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in AbCellera Biologics Inc (NASDAQ: ABCL) Right Now?
The 36-month beta value for ABCL is at 0.36. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ABCL is 223.95M, and currently, shorts hold a 10.20% of that float. The average trading volume for ABCL on June 24, 2025 was 4.89M shares.
ABCL’s Market Performance
ABCL stock saw an increase of 4.06% in the past week, with a monthly gain of 67.34% and a quarterly increase of 36.48%. The volatility ratio for the week is 6.23%, and the volatility levels for the last 30 days are 5.32% for AbCellera Biologics Inc (ABCL). The simple moving average for the past 20 days is 24.88% for ABCL’s stock, with a 24.37% simple moving average for the past 200 days.
Analysts’ Opinion of ABCL
The Benchmark Company, on the other hand, stated in their research note that they expect to see ABCL reach a price target of $9. The rating they have provided for ABCL stocks is “Buy” according to the report published on February 22nd, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to ABCL, setting the target price at $6 in the report published on December 05th of the previous year.
ABCL Trading at 37.12% from the 50-Day Moving Average
After a stumble in the market that brought ABCL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.51% of loss for the given period.
Stock Fundamentals for ABCL
Current profitability levels for the company are sitting at:
- -15.79 for the present operating margin
- -4.74 for the gross margin
The net margin for AbCellera Biologics Inc stands at -7.26. The total capital return value is set at -0.72. Equity return is now at value -15.59, with -11.96 for asset returns.
Based on AbCellera Biologics Inc (ABCL), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -1.23. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -45.34.
Currently, EBITDA for the company is -204.15 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 38.84. The receivables turnover for the company is 0.58for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.15.
Conclusion
In conclusion, AbCellera Biologics Inc (ABCL) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
